Skip to main content

Table 4 Studies on thalidomide and derivatives.

From: Radiotherapy and "new" drugs-new side effects?

Substance

Author(s)

Year

Study type

N

tumour

RT dose/ChTx/technique

Toxicity

Thalidomide

Knisely et al. [93]

2008

Phase III

332 (90 thalidomide)

Brain metastases

37,5 Gy (2,5 Gy)

53% interruptions because of side-effects

 

Chang et al. [187]

2004

Phase II

67

GBM

60 Gy (2 Gy), TMZ concomitant

10% grade III + IV neutropenia, 1% grade V; 16% grade III + IV thrombopenia, 9% grade III + IV rash, 1% grade III constipation, 9% grade III fatigue

 

Atkins et al. [188]

2008

Phase II

39

CNS metastases (melanoma)

30 Gy (3 Gy) WBRT + TMZ concomitant

10% grade III + IV + V thrombosis, 5% grade III + IV + V myelosuppression, 8% grade III + IV + V cardiac events

 

Ch'ang et al. [189]

2011

Phase II

24

HCC

50 Gy (2 Gy)

54% rash, 38% somnolence, 33% constipation

 

Turner et al. [97]

2007

Phase II

13

Brainstem glioma + GBM

55.8 Gy (1.8 Gy)

8% grade IV DVT, ≥ 15% grade III leukopenia/motoneuropathy/constipation

Lenalidomide

Drappatz et al. [101]

2009

Pilot study

23

GBM

60 Gy (2 Gy)

4% grade IV pneumonitis/hypoxia, 9% grade III nausea, 4% grade IV pulmonary embolism, 4% grade III pneumonia

  1. N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, LA-HNSCC-locally advanced head-and-neck cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis